Audentes Therapeutics
BOLD
BOLD was delisted on the 14th of January, 2020.
58 hedge funds and large institutions have $272M invested in Audentes Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 2 closing their positions.
722% more capital inflows, than outflows
Capital inflows: $24.1M | Capital outflows: $2.93M
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
2% more funds holding
Funds holding: 57 → 58 (+1)
1.57% more ownership
Funds ownership: 71.34% → 72.91% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.9M |
| 2 |
Casdin Capital
New York
|
+$4.21M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.76M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$728K |
| 5 |
Spark Investment Management
New York
|
+$448K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$748K |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$404K |
| 3 |
RTW Investments
New York
|
-$365K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$307K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$294K |
BOLD Hedge Fund Activity: Q1 2017 in Review
58 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics (BOLD) for Q1 2017, worth a combined $272M — down 3.8% from $283M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BOLD positions and 2 closed out — a net gain of 7 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $13.9M. The largest seller was AllianceBernstein, cutting an estimated $748K.
- 58 institutional investors held Audentes Therapeutics (BOLD) as of Q1 2017, up from 57 in Q4 2016.
- Funds reported $272M of Audentes Therapeutics stock for Q1 2017, down 3.8% quarter-over-quarter.
- 9 funds opened new Audentes Therapeutics positions in Q1 2017 and 2 closed out, a net change of +7 holders.
- The largest Audentes Therapeutics buyer in Q1 2017 was BlackRock, an estimated $13.9M added.
- The largest Audentes Therapeutics seller in Q1 2017 was AllianceBernstein, an estimated $748K sold.
Based on aggregated 13F filings for Q1 2017.